A recent study found that the long-term healthcare costs associated with stroke are higher than previously believed, especially for those patients suffering from intracerebral hemorrhage, highlighting the need to prevent the costly, dangerous condition.
A new microscope is transforming the kinds of questions that scientists can study. It offers more detailed and 3D images of molecules, cells and embryos for a longer time than previously possible.
Medical device companies using Apple's HealthKit are banned from storing health data on the iCloud server, according to the company's recent changes to the App Store Review Guidelines.
Johnson & Johnson scored a victory in the first case to go to trial for its metal-on-metal hip implants, as a Texas jury ruled against a woman who claimed that Pinnacle devices made by the company's DePuy subsidiary poisoned her and caused undue pain and suffering.
Edwards Lifesciences beat earnings expectations on the back of faster-than-expected growth in the company's core market of transaortic valve replacements for heart patients too frail for open-heart surgery. But company officials stressed that competitors are ramping up their efforts in that arena following recent product launches.
Physical therapy to help stroke patients regain hand motor function after a stroke is so highly repetitive that patients often struggle through it. Irvine,CA-based startup Flint Rehabilitation Devices has launched a device that could make that process more effective and less excruciating.
C.R. Bard provided more clarity around the launch strategy of the first FDA approved drug-coated balloon, the Lutonix 035 Drug Coated Balloon Catheter, during its third quarter earnings call today.
Startup Gamma Medica is aiming to improve the odds and lower the cost of effective imaging of dense breast tissue with its molecular breast imaging tool. Now, it's gained a cash infusion of $11.5 million to aid in its commercialization efforts.
Johnson & Johnson is facing grave allegations that the company, in an effort to preserve billions in profit, ignored overwhelming evidence that its Pinnacle hip implants were highly dangerous.
Expect medical device companies to feel the squeeze from the advent of reference pricing, whereby patients must bear procedures' expenses that exceed a predetermined threshold.
U.K.-based Enigma Diagnostics inked a deal with a Chinese biotech outfit and roped in $50 million to support development of its innovative molecular diagnostic system and gain headway in the country's rapidly growing med tech market.
The race to the noninvasive glucose monitor is apparently passé. Right now it's all about getting glucose level data on mobile devices as well as enabling easy analysis and sharing of the data. That's what the wireless glucose monitor from Telcare does. For its efforts, Telcare got a $32.5 million Series C round.
Med merger mania is leaving no stone unturned, even sterilization services. On the heels of Steris's bid for Britain's Synergy Health in another inversion deal, private equity firm GTCR is looking to unload Sterigenics International, another sterilization company, for $1.5 billion, including debt.
Boston Scientific expects an FDA approval of its controversial stroke-fighting device Watchman during the first half of next year coming off its third positive FDA panel, despite a checkered regulatory past that includes a 2010 rejection due to safety concerns.
Amid growing industry concern over the cybersecurity of medical devices, the U.S. government is weighing in on the issue and investigating two dozen cases of suspected cybersecurity flaws in devices and hospital equipment.
AirStrip and IBM have partnered to create a mobile monitoring solution to aid physicians in tracking and predicting the status of patients with acute and critical illnesses.
On the heels of Siemens' sale of its healthcare IT and microbiology units, the company is eyeing a sale of its hearing aid unit to private equity firm EQT Partners AB for more than $2.6 billion.
Cardiovascular device company Sorin Group has invested $20 million in Respicardia. The financing is to be used to fund ongoing clinical testing of the startup's remede System, which is a pacemaker-like device for central sleep apnea that delivers electrical pulses via an implantable lead to the phrenic nerve.
Privacy concerns and cost are two of the leading barriers to adoption of wearable medical devices, PwC said in two reports released today on the future of wearable technology.
Genomic sequencing seems to have come of age with Illumina as a substantial driver and beneficiary. During the third quarter, the company achieved astonishing revenue growth of 35% to $481 million over the same quarter last year.